Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Glaukos Corporation (GKOS : NYSE)
 
 • Company Description   
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.

Number of Employees: 727

 
 • Price / Volume Information   
Yesterday's Closing Price: $39.34 Daily Weekly Monthly
20 Day Moving Average: 721,383 shares
Shares Outstanding: 47.33 (millions)
Market Capitalization: $1,862.12 (millions)
Beta: 1.52
52 Week High: $87.24
52 Week Low: $33.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -34.38% -26.10%
12 Week -27.48% -20.28%
Year To Date -11.48% 7.31%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
229 AVENIDA FABRICANTE
-
SAN CLEMENTE,CA 92672
USA
ph: 949-367-9600
fax: 949-367-9984
investors@glaukos.com http://www.glaukos.com
 
 • General Corporate Information   
Officers
Thomas W. Burns - Chief Executive Officer; President and Chairman of
Joseph E. Gilliam - Chief Financial Officer & SVP; Corporate Developme
David F. Hoffmeister - Director
Marc A. Stapley - Director
Aimee S. Weisner - Director

Peer Information
Glaukos Corporation (ABMD)
Glaukos Corporation (DMDS)
Glaukos Corporation (CPWY.)
Glaukos Corporation (EQUR)
Glaukos Corporation (ECIA)
Glaukos Corporation (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 377322102
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 47.33
Most Recent Split Date: (:1)
Beta: 1.52
Market Capitalization: $1,862.12 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.94 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.12
Price/Cash Flow: -
Price / Sales: 6.34
EPS Growth
vs. Year Ago Period: -80.95%
vs. Previous Quarter: -22.58%
Sales Growth
vs. Year Ago Period: -0.42%
vs. Previous Quarter: -7.59%
ROE
03/31/22 - -7.95
12/31/21 - -6.55
09/30/21 - -4.12
ROA
03/31/22 - -4.48
12/31/21 - -3.70
09/30/21 - -2.43
Current Ratio
03/31/22 - 8.84
12/31/21 - 7.67
09/30/21 - 7.91
Quick Ratio
03/31/22 - 8.39
12/31/21 - 7.31
09/30/21 - 7.60
Operating Margin
03/31/22 - -16.04
12/31/21 - -13.16
09/30/21 - -8.56
Net Margin
03/31/22 - -9.45
12/31/21 - -16.87
09/30/21 - -13.05
Pre-Tax Margin
03/31/22 - -9.32
12/31/21 - -16.76
09/30/21 - -13.92
Book Value
03/31/22 - 12.63
12/31/21 - 12.52
09/30/21 - 12.91
Inventory Turnover
03/31/22 - 3.16
12/31/21 - 3.53
09/30/21 - 4.06
Debt-to-Equity
03/31/22 - 0.59
12/31/21 - 0.60
09/30/21 - 0.59
Debt-to-Capital
03/31/22 - 37.13
12/31/21 - 37.53
09/30/21 - 36.97
 

Powered by Zacks Investment Research ©